表紙:肝炎ウイルス診断検査:医療機器のパイプライン評価
市場調査レポート
商品コード
398053

肝炎ウイルス診断検査:医療機器のパイプライン評価

Hepatitis C Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)

出版日: | 発行: GlobalData | ページ情報: 英文 | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.50円
肝炎ウイルス診断検査:医療機器のパイプライン評価
出版日: 2021年06月30日
発行: GlobalData
ページ情報: 英文
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の肝炎ウイルス診断検査の関連市場における、主要なパイプライン製品 (医療機器) とその治験の進行状況について調査すると共に、製品特性の比較分析 (治験の進行段階別) や、主要企業のプロファイルおよび代表的製品、昨今の市場動静 (資本取引・事業提携など) といった情報を取りまとめてお届けいたします。

第1章 目次

第2章 イントロダクション

  • 肝炎ウイルス診断検査の概要

第3章 現在治験中の製品

  • パイプライン製品:治験段階別
  • パイプライン製品:領域別
  • パイプライン製品:規制経路別
  • パイプライン製品:推定認証時期別

第4章 肝炎ウイルス診断検査:各企業で現在治験中のパイプライン製品

  • 肝炎ウイルス診断検査の企業:治験段階別のパイプライン製品
  • 肝炎ウイルス診断検査:治験段階別のパイプライン製品

第5章 肝炎ウイルス診断検査の企業・製品の概要

  • Abbott Diagnostics Diagnostic Tests
    • パイプライン製品および進行中の治験の概要
  • Access Bio, Inc.
  • Alderon Biosciences, Inc.
  • Alere Inc
  • AutoGenomics Inc
  • AXO Science SAS
  • BCR Corp
  • Beckman Coulter Inc
  • Biokit, S.A.
  • Biomagnetics Diagnostics Corporation (Inactive)
  • Bio-Rad Laboratories Inc
  • CeMines, Inc.
  • Cepheid
  • China Medical Technologies Inc
  • Co-Diagnostics HBDC, Inc.
  • Corgenix Medical Corp
  • Da An Gene Co Ltd
  • Diagnostics for the Real World (Europe) Ltd.
  • DiaSorin S.p.A
  • D-Kimia, LLC.
  • Ecoli s.r.o.
  • Enzo Biochem Inc
  • Fast-track diagnostics S.a.r.l.
  • Ferrer inCode SL
  • French National Institute of Health and Medical Research
  • genedrive plc
  • Genera Biosystems Ltd
  • GenMark Diagnostics Inc
  • Goodgene Inc
  • Hologic Inc
  • Imperial College London
  • MedMira Inc.
  • Mindray Medical International Ltd
  • MND Diagnostic LTD
  • Molbio Diagnostics Pvt. Ltd.
  • NanoDiagX
  • OPKO Health Inc
  • Orangelife
  • Pathogenica Inc
  • ProteinLogic Ltd
  • Qiagen NV
  • Quotient Limited
  • Resultados y Calidad del Sistema Sanitario Publico de Andalucia
  • Roche Diagnostics International Ltd
  • Sansure Biotech Inc
  • Siemens Healthcare GmbH
  • Stanford University
  • Syamala Srinivasa Life Sciences Pvt.
  • The University of British Columbia
  • University Medical Center Hamburg-Eppendorf
  • University of Texas Medical Branch at Galveston
  • University of Warwick Company Overview
  • Ustar Biotechnologies (Hangzhou) Ltd.
  • Xiamen Zeesan Biotech Co.,Ltd

第6章 肝炎ウイルス診断検査市場:昨今の動向 (全83件)

第7章 提言

図表一覧

目次
Product Code: GDME632MM

Hepatitis C Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on Hepatitis C Tests market for the year 2020 and beyond. Hepatitis C is a viral infection caused by hepatitis C virus (HCV). Hepatitis C virus is a blood borne virus that causes liver disease and can cause acute and chronic hepatitis. Infection may be caused through injection drug use, transfusion of unscreened blood products, unsafe injection practices, sexual contact and from infected mother to her baby.

Diagnosis of HCV infection can be done by screening for anti-HCV antibodies along with a serological test to confirm the viral infection. Nucleic acid test for HCV ribonucleic acid (RNA) is performed in case of positive test results for anti HCV antibodies to confirm chronic infection. Since there is no vaccine available for HCV infection, the World Health Organization (WHO) recommends blood tests to screen patients that are at an increased risk of HCV infection and reducing the risk of HCV exposure in health care settings. Screening of pregnant women for HCV is standard of care in most countries and considered to be a cost-effective strategy for reducing the risk of transmission to the baby.

The Hepatitis C virus tests includes Hepatitis C Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Tests, Hepatitis C Nucleic Acid Amplification Tests (NAATs) and Multi-parameter HIV, Hepatitis B, and Hepatitis C Nucleic Acid Amplification Tests (NAATs).

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are -

Currently marketed Hepatitis C Tests and evolving competitive landscape -

  • Insightful review of the key industry trends.
  • Annualized total Hepatitis C Tests market revenue by segment and market outlooks from 2015-2030.
  • Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights -

  • Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
  • SWOT analysis for Hepatitis C Tests market.
  • Competitive dynamics insights and trends provided for Hepatitis C Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

  • Country specific overview of the healthcare system.
  • Country specific reimbursement policies.
  • Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered - Abbott Laboratories, Siemens Healthineers AG, Grifols SA, F. Hoffmann-La Roche Ltd, Ortho-Clinical Diagnostics Inc, Hologic Inc, Others

Countries covered - United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

Who should buy this report?

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

  • CMO executives who must have deep understanding of the Hepatitis C Tests market place to make strategic planning and investment decisions.
  • Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
  • Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

  • Understand the impact of COVID-19 on Hepatitis C Tests market.
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving Hepatitis C Tests.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Hepatitis C Tests market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track device sales in the global and country-specific Hepatitis C Tests market from 2015-2030.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.